William A Liss, MD
Dermatology · Monterey
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 20
- 4 carriers
- Office
- 1
Offices
1 location · Csi Medical Group · 104 clinicians in this group
Looking this up.
Hospitals listed: Community Hospital of the Monterey Peninsula. That is not proof they admit you there this week.
Plans that list them
20 plans · 4 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Liss’s office at (831) 333-9008 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
20 of 20 plans
| Advantage Care (HMO) | Align Senior Care | Listed | Oct 1, 2026 |
| Premier Care (HMO I-SNP) | Align Senior Care | Listed | Oct 1, 2026 |
| Senior Care (HMO I-SNP) | Align Senior Care | Listed | Oct 1, 2026 |
| Alignment Health Advantage PPO (PPO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
California Medical Board record
Licence G74006 · Current
Licensed to practise in California · since 1992 · expires 2027-12-31 · Ohio State University College of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Community Hospital of the Monterey PeninsulaMonterey, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Montage HealthPatients rate it 4 of 5 · 84% would definitely recommend itOverall rating: 4 of 5 starsWorse than the national rate — CMS Medicare PSI 90: Patient safety and adverse events composite: 1.48 (1.22 to 1.74), Jul 2022 – Jun 2024Worse than the national rate — Postoperative acute kidney injury requiring dialysis rate: 3.12 (1.69 to 4.56) · 1,095 cases, Jul 2022 – Jun 2024Worse than the national rate — Postoperative respiratory failure rate: 19.24 (14.17 to 24.3) · 1,118 cases, Jul 2022 – Jun 2024Worse than the national rate — Postoperative sepsis rate: 9.62 (6.42 to 12.82) · 1,086 cases, Jul 2022 – Jun 2024Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.39, Oct 2024 – Sep 2025
See every measure and the patient survey for Community Hospital of the Monterey Peninsula
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 1 better, 5 the same, 1 worse of 7 measures. Readmissions: 0 better, 11 the same, 0 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.48 (1.22 to 1.74) | Worse | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 3.12 (1.69 to 4.56) · 1,095 cases | Worse | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 19.24 (14.17 to 24.3) · 1,118 cases | Worse | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 9.62 (6.42 to 12.82) · 1,086 cases | Worse | Jul 2022 – Jun 2024 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.39 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.27 (0.39 to 2.16) · 1,873 cases | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 158.2 (110.65 to 205.75) · 140 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.3 · 74 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.8 · 135 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10 · 184 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.7 · 686 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 16.4 · 1,072 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8 · 328 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.8 · 3,300 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.29 (0.11 to 0.48) · 10,234 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.1 to 0.46) · 10,572 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.25 (1.47 to 5.04) · 2,617 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.37 (1.04 to 3.7) · 2,519 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.21 (0.75 to 3.66) · 744 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.61 (0.06 to 1.17) · 8,715 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 5.2 · 156 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.28 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.799 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.732 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.7 · 152 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.6 · 625 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 6.3 · 193 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -3.2 · 749 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 7 · 1,074 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.5 · 850 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4 (2.7 to 5.8) · 224 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13.5 (10.4 to 17.4) · 224 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.7 · 153 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11.5 · 49 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.3 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 14.2 (10.9 to 18.6) · 711 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.2 (1 to 1.5) · 746 cases | No different | Jan 2024 – Dec 2024 |
What patients said (520 patients answered, 28% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 5 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 62% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 84% |
| Doctors "always" explained things so they could understand | 75% |
| Doctors "always" listened carefully | 79% |
| Doctors "always" treated them with courtesy and respect | 89% |
| Patients who gave a rating of "9" or "10" (high) | 82% |
| Staff "always" explained new medications | 79% |
| Nurses "always" explained things so they could understand | 79% |
| Nurses "always" listened carefully | 77% |
| Nurses "always" treated them with courtesy and respect | 89% |
| "Always" quiet at night | 54% |
| "YES", patients would definitely recommend the hospital | 84% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
Original Medicare doctor bills
$92,238
Medicare paid this office $92,238 for 469 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Short return visit (20+ min) | 272 | $24,281 | $75 |
| Destruction of precancer skin growth, 1 growth | 240 | $13,778 | $49 |
| Destruction of skin growth, 1-14 growths | 81 | $8,672 | $97 |
| Biopsy of related skin growth, first growth | 87 | $7,959 | $83 |
| Destruction of precancer skin growth, 2-14 growths | 194 | $7,144 | $6 |
See all 12 services
| Short return visit (20+ min) | 272 | $24,281 | $75 |
| Destruction of precancer skin growth, 1 growth | 240 | $13,778 | $49 |
| Destruction of skin growth, 1-14 growths | 81 | $8,672 | $97 |
| Biopsy of related skin growth, first growth | 87 | $7,959 | $83 |
| Destruction of precancer skin growth, 2-14 growths | 194 | $7,144 | $6 |
| New patient visit (30+ min) | 63 | $5,646 | $90 |
| Short return visit | 98 | $4,826 | $47 |
| Return visit (30+ min) | 28 | $3,250 | $108 |
| Destruction of precancer skin growth, 15 or more growths | 12 | $1,901 | $146 |
| Destruction of cancer skin growth of trunk, arms, or legs, 1.1-2.0 cm | 11 | $1,864 | $143 |
| Biopsy of related skin growth, each additional growth | 27 | $1,672 | $44 |
| New patient visit (15+ min) | 20 | $1,231 | $62 |
Procedures Medicare counted
| Melanoma (skin cancer) excision | 1-10 | None |
| Removal of skin lesions | 1776 | More than 97% of doctors who do this |
| Removal or shaving of skin growth | 17 | More than 70% of doctors who do this |
| Skin biopsy | 403 | More than 94% of doctors who do this |
Who their Medicare patients are
469 Original Medicare patients in 2024. Average age 75 · Under 65 4% · 85 and older 11% · Women 36% · Also on Medicaid 15% · Health risk score 0.98. At or below the middle of the specialty; the typical dermatology clinician is at 1.01.
Conditions among them: High blood pressure 61% · Coronary heart disease 27% · Cancer 18% · Diabetes 17% · Chronic kidney disease 15% · Atrial fibrillation 15% · Depression 13% · COPD 12% · Heart failure 10% · Stroke 6% · Dementia 5%.
The office billed $218,884, Medicare allowed $118,230 and paid $92,238; for 2,384 services of 42 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 469 | 2,384 | 75 | 0.98 | $218,884 | $92,238 |
| 2023 | 32 | 87 | 77 | 1.12 | $12,697 | $4,886 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 2 services
| Short return visit | 13 | $762 | $54 |
| Destruction of precancer skin growth, 1 growth | 12 | $672 | $56 |
Medicaid work
$588,141 in 2024
Medicaid paid $588,141 for 6,926 billed services this clinician did in 2024, up to 138 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Clinic visit/encounter, all-inclusive | 1,276 | $454,941 |
| Service | 1,624 | $133,200 |
| OFFICE/OUTPATIENT NEW SF MDM 15 MINUTES | 1,418 | $0 |
| Short return visit (20+ min) | 1,380 | $0 |
| Service | 1,228 | $0 |
| 2024 | 6,926 | 5 | 138 | $588,141 |
| 2023 | 6,953 | 7 | 118 | $617,896 |
| 2022 | 5,119 | 5 | 92 | $450,877 |
See the largest Medicaid services in earlier years
2023
| Clinic visit/encounter, all-inclusive | 1,395 | $482,413 |
| Service | 1,652 | $135,483 |
| Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use | 14 | $0 |
| OFFICE/OUTPATIENT NEW SF MDM 15 MINUTES | 1,381 | $0 |
| Short return visit (20+ min) | 1,226 | $0 |
| Return visit (30+ min) | 41 | $0 |
| Service | 1,244 | $0 |
2022
| Clinic visit/encounter, all-inclusive | 1,009 | $339,713 |
| Service | 1,356 | $111,164 |
| OFFICE/OUTPATIENT NEW SF MDM 15 MINUTES | 1,447 | $0 |
| Short return visit (20+ min) | 362 | $0 |
| Service | 945 | $0 |
Drugs they prescribed that Part D paid
$700,082
Pharmacies billed $700,082 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 728) in 2024. At or below the middle of the specialty; the typical dermatology clinician is at 0%.
631 generic and 97 brand-name prescriptions · $700,082 in drug cost · 71 antibiotic prescriptions to 34 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Dupixent | 22 | $80,138 | $3,643 |
| Otezla | 12 | $56,429 | $4,702 |
| Calcipotriene | 15 | $4,637 | $309 |
| Tacrolimus | 20 | $4,275 | $214 |
| Fluocinonide | 64 | $3,328 | $52 |
See all 18 drugs
| Dupixent | 22 | $80,138 | $3,643 |
| Otezla | 12 | $56,429 | $4,702 |
| Calcipotriene | 15 | $4,637 | $309 |
| Tacrolimus | 20 | $4,275 | $214 |
| Fluocinonide | 64 | $3,328 | $52 |
| Clobetasol Propionate | 31 | $2,490 | $80 |
| Clindamycin Phosphate | 28 | $1,281 | $46 |
| Doxycycline Hyclate | 33 | $1,103 | $33 |
| Metronidazole | 19 | $1,057 | $56 |
| Doxycycline Monohydrate | 23 | $1,031 | $45 |
| Triamcinolone Acetonide | 126 | $990 | $8 |
| Ketoconazole | 56 | $801 | $14 |
| Tretinoin | 12 | $511 | $43 |
| Ammonium Lactate | 21 | $452 | $22 |
| Terbinafine | 27 | $366 | $14 |
| Clotrimazole | 19 | $328 | $17 |
| Hydrocortisone | 55 | $306 | $6 |
| Hydroxyzine | 18 | $61 | $3 |
Year by year
| 2024 | 728 | 231 | 0% (0) | 13% | $700,082 |
| 2023 | 483 | 150 | 0% (0) | 12% | $405,069 |
| 2022 | 408 | 189 | 0% (0) | 10% | $306,864 |
| 2021 | 653 | 263 | None | 15% | $402,453 |
| 2020 | 652 | 292 | None | 19% | $357,662 |
| 2019 | 604 | 249 | 0% (0) | 18% | $222,295 |
| 2018 | 574 | 243 | None | 21% | $143,851 |
| 2017 | 583 | 259 | 0% (0) | 20% | $110,378 |
| 2016 | 527 | 260 | 0% (0) | 26% | $69,940 |
| 2015 | 501 | 236 | 0% (0) | 17% | $61,938 |
| 2014 | 543 | 239 | 0% (0) | 17% | $48,780 |
| 2013 | 465 | 218 | None | 22% | $46,089 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 12 drugs
| Taltz | 22 | $163,611 | $7,437 |
| Tacrolimus | 14 | $5,988 | $428 |
| Clobetasol Propionate | 28 | $4,748 | $170 |
| Fluocinonide | 47 | $3,613 | $77 |
| Doxycycline Monohydrate | 18 | $1,228 | $68 |
| Triamcinolone Acetonide | 80 | $1,149 | $14 |
| Clindamycin Phosphate | 21 | $639 | $30 |
| Ammonium Lactate | 24 | $563 | $23 |
| Hydrocortisone | 37 | $454 | $12 |
| Hydroxyzine | 19 | $403 | $21 |
| Clotrimazole | 16 | $326 | $20 |
| Ketoconazole | 14 | $279 | $20 |
2022: 10 drugs
| Otezla | 13 | $63,337 | $4,872 |
| Doxycycline Monohydrate | 21 | $2,840 | $135 |
| Fluocinonide | 43 | $2,194 | $51 |
| Clobetasol Propionate | 19 | $2,087 | $110 |
| Triamcinolone Acetonide | 71 | $1,045 | $15 |
| Fluocinolone Acetonide | 12 | $644 | $54 |
| Hydrocortisone | 36 | $474 | $13 |
| Clindamycin Phosphate | 11 | $291 | $26 |
| Ammonium Lactate | 11 | $286 | $26 |
| Fluconazole | 11 | $146 | $13 |
2021: 15 drugs
| Otezla | 48 | $198,423 | $4,134 |
| Humira | 13 | $55,004 | $4,231 |
| Dupixent | 12 | $38,035 | $3,170 |
| Fluocinonide | 63 | $3,519 | $56 |
| Clobetasol Propionate | 58 | $3,102 | $53 |
| Fluorouracil | 38 | $2,239 | $59 |
| Metronidazole | 35 | $1,495 | $43 |
| Fluocinolone Acetonide | 34 | $1,284 | $38 |
| Triamcinolone Acetonide | 97 | $1,115 | $11 |
| Doxycycline Monohydrate | 36 | $1,094 | $30 |
| Hydrocortisone | 45 | $685 | $15 |
| Methotrexate | 23 | $391 | $17 |
| Clindamycin Phosphate | 16 | $351 | $22 |
| Terbinafine | 12 | $208 | $17 |
| Mupirocin | 11 | $150 | $14 |
2020: 15 drugs
| Otezla | 66 | $211,296 | $3,201 |
| Dupixent | 13 | $40,246 | $3,096 |
| Fluocinonide | 51 | $3,736 | $73 |
| Fluorouracil | 57 | $3,701 | $65 |
| Clobetasol Propionate | 56 | $3,274 | $58 |
| Betamethasone Diprop Augmented | 13 | $2,059 | $158 |
| Fluocinolone Acetonide | 36 | $1,596 | $44 |
| Doxycycline Monohydrate | 30 | $1,001 | $33 |
| Metronidazole | 23 | $1,000 | $43 |
| Hydroxychloroquine Sulfate | 20 | $972 | $49 |
| Triamcinolone Acetonide | 80 | $941 | $12 |
| Retin-A | 13 | $897 | $69 |
| Clindamycin Phosphate | 27 | $670 | $25 |
| Hydrocortisone | 41 | $659 | $16 |
| Methotrexate | 20 | $333 | $17 |
2019: 16 drugs
| Otezla | 42 | $128,505 | $3,060 |
| Dupixent | 12 | $36,535 | $3,045 |
| Fluocinonide | 65 | $6,855 | $105 |
| Clobetasol Propionate | 46 | $5,738 | $125 |
| Betamethasone Diprop Augmented | 15 | $2,289 | $153 |
| Fluorouracil | 22 | $2,061 | $94 |
| Hydroxychloroquine Sulfate | 20 | $1,830 | $92 |
| Triamcinolone Acetonide | 75 | $1,670 | $22 |
| Fluocinolone Acetonide | 24 | $1,299 | $54 |
| Vectical | 11 | $1,163 | $106 |
| Metronidazole | 24 | $1,038 | $43 |
| Retin-A | 13 | $768 | $59 |
| Clindamycin Phosphate | 26 | $736 | $28 |
| Hydrocortisone | 41 | $687 | $17 |
| Doxycycline Monohydrate | 22 | $682 | $31 |
| Methotrexate | 18 | $346 | $19 |
2018: 18 drugs
| Otezla | 23 | $67,655 | $2,942 |
| Dupixent | 11 | $32,107 | $2,919 |
| Betamethasone Diprop Augmented | 34 | $8,358 | $246 |
| Fluocinonide | 44 | $5,188 | $118 |
| Clobetasol Propionate | 21 | $2,302 | $110 |
| Fluorouracil | 14 | $2,210 | $158 |
| Triamcinolone Acetonide | 75 | $2,015 | $27 |
| Hydroxychloroquine Sulfate | 33 | $1,805 | $55 |
| Retin-A | 26 | $1,547 | $59 |
| Metronidazole | 22 | $1,361 | $62 |
| Fluocinolone Acetonide | 17 | $1,189 | $70 |
| Methotrexate | 26 | $1,106 | $43 |
| Hydrocortisone | 40 | $755 | $19 |
| Clindamycin Phosphate | 23 | $683 | $30 |
| Alclometasone Dipropionate | 11 | $682 | $62 |
| Doxycycline Monohydrate | 23 | $626 | $27 |
| Terbinafine | 13 | $211 | $16 |
| Acyclovir | 15 | $204 | $14 |
2017: 18 drugs
| Otezla | 22 | $50,113 | $2,278 |
| Fluocinonide | 48 | $5,547 | $116 |
| Fluocinolone Acetonide | 28 | $4,391 | $157 |
| Clobetasol Propionate | 24 | $3,143 | $131 |
| Fluorouracil | 19 | $3,121 | $164 |
| Metronidazole | 25 | $2,595 | $104 |
| Betamethasone Dipropionate | 14 | $2,191 | $156 |
| Triamcinolone Acetonide | 68 | $1,857 | $27 |
| Doxycycline Monohydrate | 44 | $1,398 | $32 |
| Retin-A | 23 | $1,279 | $56 |
| Clindamycin Phosphate | 20 | $1,201 | $60 |
| Hydroxychloroquine Sulfate | 16 | $1,135 | $71 |
| Hydrocortisone | 45 | $621 | $14 |
| Methotrexate | 11 | $431 | $39 |
| Acyclovir | 23 | $349 | $15 |
| Mupirocin | 15 | $243 | $16 |
| Sulfamethoxazole-Trimethoprim | 11 | $187 | $17 |
| Cephalexin | 12 | $169 | $14 |
2016: 14 drugs
| Clobetasol Propionate | 33 | $11,214 | $340 |
| Fluocinolone Acetonide | 30 | $5,910 | $197 |
| Fluocinonide | 51 | $5,462 | $107 |
| Fluorouracil | 21 | $3,108 | $148 |
| Clindamycin Phosphate | 30 | $3,014 | $100 |
| Triamcinolone Acetonide | 67 | $2,880 | $43 |
| Metronidazole | 18 | $2,114 | $117 |
| Doxycycline Monohydrate | 37 | $1,533 | $41 |
| Retin-A | 23 | $1,226 | $53 |
| Alclometasone Dipropionate | 14 | $736 | $53 |
| Hydrocortisone | 29 | $529 | $18 |
| Methotrexate | 12 | $493 | $41 |
| Acyclovir | 15 | $273 | $18 |
| Cephalexin | 12 | $190 | $16 |
2015: 12 drugs
| Clobetasol Propionate | 44 | $8,976 | $204 |
| Fluorouracil | 26 | $6,528 | $251 |
| Fluocinonide | 49 | $6,188 | $126 |
| Fluocinolone Acetonide | 26 | $5,122 | $197 |
| Metronidazole | 37 | $3,482 | $94 |
| Triamcinolone Acetonide | 68 | $2,763 | $41 |
| Clindamycin Phosphate | 20 | $2,245 | $112 |
| Doxycycline Monohydrate | 34 | $2,157 | $63 |
| Desonide | 12 | $1,041 | $87 |
| Retin-A | 11 | $526 | $48 |
| Hydrocortisone | 18 | $350 | $19 |
| Methotrexate | 13 | $332 | $26 |
2014: 13 drugs
| Fluorouracil | 26 | $6,532 | $251 |
| Fluocinonide | 94 | $5,516 | $59 |
| Metronidazole | 39 | $4,035 | $103 |
| Fluocinolone Acetonide | 19 | $3,596 | $189 |
| Clobetasol Propionate | 58 | $2,075 | $36 |
| Doxycycline Monohydrate | 29 | $1,896 | $65 |
| Clindamycin Phosphate | 19 | $1,864 | $98 |
| Desonide | 18 | $1,850 | $103 |
| Imiquimod | 12 | $1,608 | $134 |
| Triamcinolone Acetonide | 50 | $1,578 | $32 |
| Methotrexate | 18 | $902 | $50 |
| Retin-A | 14 | $410 | $29 |
| Hydrocortisone | 19 | $345 | $18 |
2013: 11 drugs
| Fluorouracil | 24 | $6,504 | $271 |
| Metronidazole | 32 | $4,397 | $137 |
| Fluocinonide | 49 | $3,169 | $65 |
| Desonide | 40 | $2,935 | $73 |
| Clindamycin Phosphate | 25 | $2,376 | $95 |
| Doxycycline Hyclate | 27 | $2,297 | $85 |
| Triamcinolone Acetonide | 56 | $2,117 | $38 |
| Vectical | 15 | $2,060 | $137 |
| Clobetasol Propionate | 39 | $1,134 | $29 |
| Retin-A | 22 | $556 | $25 |
| Methotrexate | 12 | $415 | $35 |
Money from drug and device companies
$1,206 in 2025
| 2025 | 9 | 39 | None | $1,206 |
| 2024 | 4 | 16 | None | $983 |
| 2023 | 5 | 5 | None | $404 |
| 2022 | 1 | 1 | None | $12 |
| 2019 | 1 | 2 | None | $90 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Galderma Laboratories L.P. | Nemluvio | $305 | 5 payments
|
| Abbvie | Skyrizi | $218 | 11 payments
|
| Arcutis Biotherapeutics | Zoryve | $210 | 7 payments
|
| Incyte | Opzelura | $196 | 5 payments
|
| E.R. Squibb & Sons L.L.C. | Sotyktu | $107 | 5 payments
|
| Novartis Pharmaceuticals | Cosentyx | $58 | 2 payments
|
See all 39 published payments
| Abbvie | Meals · 2025-12-15 | Skyrizi | $6 |
| Abbvie | Meals · 2025-12-10 | Skyrizi | $11 |
| Galderma Laboratories L.P. | Meals · 2025-11-20 | Nemluvio | $100 |
| Incyte | Meals · 2025-11-12 | Opzelura | $26 |
| Abbvie | Meals · 2025-10-29 | Skyrizi | $27 |
| Abbvie | Meals · 2025-10-28 | Rinvoq | $25 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-10-27 | Sotyktu | $20 |
| Galderma Laboratories L.P. | Meals · 2025-10-22 | Nemluvio | $128 |
| Arcutis Biotherapeutics | Meals · 2025-10-22 | Zoryve | $141 |
| Galderma Laboratories L.P. | Meals · 2025-10-20 | Nemluvio | $25 |
| Ucb | Meals · 2025-10-16 | Bimzelx | $21 |
| Incyte | Meals · 2025-09-30 | Opzelura | $10 |
| Genzyme | Meals · 2025-09-29 | Ayvakit | $38 |
| Galderma Laboratories L.P. | Meals · 2025-09-24 | Nemluvio | $25 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-09-22 | Sotyktu | $21 |
| STRATA Skin Sciences | Meals · 2025-09-09 | Xtrac | $25 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-09-03 | Sotyktu | $25 |
| Arcutis Biotherapeutics | Meals · 2025-09-03 | Zoryve | $16 |
| Abbvie | Meals · 2025-08-06 | Skyrizi | $14 |
| Abbvie | Meals · 2025-08-06 | Rinvoq | $20 |
| Arcutis Biotherapeutics | Meals · 2025-07-31 | Zoryve | $16 |
| Novartis Pharmaceuticals | Meals · 2025-07-16 | Cosentyx | $27 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-07-07 | Sotyktu | $21 |
| Galderma Laboratories L.P. | Meals · 2025-06-27 | Nemluvio | $26 |
| Abbvie | Meals · 2025-06-25 | Rinvoq | $18 |
| Abbvie | Meals · 2025-06-12 | Skyrizi | $23 |
| Incyte | Meals · 2025-06-10 | Opzelura | $21 |
| Incyte | Meals · 2025-06-09 | Opzelura | $113 |
| Novartis Pharmaceuticals | Meals · 2025-06-04 | Cosentyx | $31 |
| Arcutis Biotherapeutics | Meals · 2025-05-27 | Zoryve | $3 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-05-21 | Sotyktu | $21 |
| Arcutis Biotherapeutics | Meals · 2025-04-29 | Zoryve | $10 |
| Arcutis Biotherapeutics | Meals · 2025-04-29 | Zoryve | $2 |
| Abbvie | Meals · 2025-03-26 | Skyrizi | $24 |
| Abbvie | Meals · 2025-03-18 | Skyrizi | $31 |
| Arcutis Biotherapeutics | Meals · 2025-03-04 | Zoryve | $22 |
| Ucb | Meals · 2025-02-19 | Bimzelx | $28 |
| Abbvie | Meals · 2025-02-06 | Skyrizi | $18 |
| Incyte | Meals · 2025-01-22 | Opzelura | $27 |
See earlier years (2024, 2023, 2022, 2019)
2024: $983
| E.R. Squibb & Sons L.L.C. | Sotyktu | $597 | 8 payments
|
| Abbvie | Skyrizi | $355 | 6 payments
|
| Arcutis Biotherapeutics | Zoryve | $17 | 1 payment
|
| Novartis Pharmaceuticals | Cosentyx | $14 | 1 payment
|
2023: $404
| Incyte | Opzelura | $124 | 1 payment
|
| Janssen Biotech | Tremfya | $117 | 1 payment
|
| E.R. Squibb & Sons L.L.C. | Sotyktu | $115 | 1 payment
|
| Dermavant Sciences | Vtama | $27 | 1 payment
|
| Lilly USA | Taltz | $22 | 1 payment
|
2022: $12
| Journey Medical | Qbrexza | $12 | 1 payment
|
2019: $90
| Lilly USA | Taltz | $90 | 2 payments
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 98.3 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1740368828
- Licence
- CA G74006California G74006: Current · expires 2027-12-31
- Trained
- Ohio State University College of Medicine, 1988
- Group
- Csi Medical Group
- Gender
- Male
More record details
- Sole proprietor
- No
- Medicaid ID
- CA 00G740060
- Taxonomy
- Federal specialty code 207N00000X (207N00000X)
- Mailing address
- 1800 Harrison St Fl 7, Oakland, CA, 94612
- NPI first listed
- 2006-11-02
- NPI last updated
- 2024-05-10
- NPI record certified
- 2024-05-10
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 9460 N Name Uno Ste 210, Gilroy, CA, 95020 · 9781 Blue Larkspur Ln, Monterey, CA, 93940 · 114 E Romie Ln, Salinas, CA, 93901
This office lists an electronic records connection.